MIMEDX Announces Speakers for December 7 Investor Day

Rhea-AI Summary

MIMEDX (Nasdaq: MDXG) plans to host a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. CEO Timothy R. Wright will share insights from their knee osteoarthritis clinical study, highlighting significant outcomes in WOMAC scores with p-values below 0.05 at three months and below 0.01 at six months. The event will also cover growth strategies and advancements in their commercial business. Key speakers will include executives and third-party experts discussing the musculoskeletal pipeline and market opportunities. Registrations can be made using the access code ‘MDXG.’

Positive

• MIMEDX's knee osteoarthritis study showed statistically significant outcomes with p-values < 0.05 at three months and < 0.01 at six months.
• The company expects to achieve double-digit growth in 2022 by leveraging market development and product innovation.

Negative

• None.

Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET

MARIETTA, Ga., Nov. 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the speakers for its upcoming virtual Investor Day that will be held on Tuesday, December 7, 2021 at 9:00 a.m. ET.

Timothy R. Wright, MIMEDX Chief Executive Officer, commented, “Our team is excited to share additional analyses from the Company’s knee osteoarthritis (KOA) clinical study, following the third-party review and validation of both a statistically significant and clinically meaningful outcome in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total, WOMAC Pain and WOMAC Function scores for the Pre-Interim Analysis Cohort of 190 patients, with probability values less than 0.05 at three months and less than 0.01 at six months. We also look forward to discussing the strong growth potential for our commercial business as we capitalize on market development strategies, global expansion opportunities and product innovation initiatives to deliver double-digit growth in 2022 and beyond.”

The MIMEDX Investor Day will feature Company leadership, third-party experts and key opinion leaders who will provide updates on the musculoskeletal late-stage pipeline and robust commercial business.

Speakers and topics include:

Company Updates

• Timothy R. Wright, Chief Executive Officer, MIMEDX
• Peter M. Carlson, EVP, Chief Financial Officer, MIMEDX

Musculoskeletal Pipeline
KOA Key Findings & Path Forward

• Robert B. Stein, M.D., Ph.D., EVP, Research and Development, MIMEDX
• Michelle Massee, AVP, Product Development, MIMEDX
• Thomas M. Mick, M.D., Medical Director, Clinical Development, MIMEDX
• Vibeke Strand, M.D., Stanford University School of Medicine
• Kris J. Alden, M.D., Ph.D., Orthopaedic Surgeon, Hip, Knee & Shoulder Reconstruction
  

Commercial Business
Growth Strategy & Market Opportunity

• Rohit Kashyap, Ph.D., EVP, Chief Commercial Officer, MIMEDX
• John Harper, Ph.D., SVP R&D, Chief Technology Officer, MIMEDX
• William H. Tettelbach, M.D., Principal Medical Officer, Head of Medical Affairs, MIMEDX
• Bidhan B. Das, M.D., Colon, Rectal & General Surgeon
• Caroline Clarke, M.D., Plastic, Reconstructive & Cosmetic Surgeon
• Jonathan Labovitz, D.P.M., Western University of Health Sciences

Registration Details

A live webcast will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com at the time of the event. To register for the webcast, participants must use access code ‘MDXG.’ Participants will have the opportunity to submit written questions to MIMEDX presenters via the webcast. A replay of the webcast will be available on the Company’s website following the conclusion of the event.

About MIMEDX

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com

Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com

FAQ

What date is the MIMEDX virtual Investor Day scheduled?

The MIMEDX virtual Investor Day is scheduled for December 7, 2021.

What significant results from the knee osteoarthritis study will be discussed at the MIMEDX Investor Day?

The Investor Day will highlight significant outcomes in WOMAC scores from the knee osteoarthritis study, with p-values less than 0.05 at three months and less than 0.01 at six months.

How can I register for the MIMEDX Investor Day webcast?

To register for the MIMEDX Investor Day webcast, participants must use the access code ‘MDXG’ on the company's website.

Who are some of the speakers at the MIMEDX Investor Day?

Speakers at the MIMEDX Investor Day include CEO Timothy R. Wright and other key executives, as well as third-party experts.